International Journal of Polymeric Materials and Polymeric Biomaterials ( IF 3.2 ) Pub Date : 2023-01-03 , DOI:
10.1080/00914037.2022.2163639AbstractThe most recent WHO statistics of the year 2020 shows that lung cancer accounts for the maximum cancer mortality cases, with 1.8 million deaths annually. The current treatment strategies for lung cancer involve the three classical approaches adopted in all types of cancer, that is, chemotherapy, radiation therapy, and surgical procedures. Apart from these, radiofrequency ablation, immunotherapy, and palliative care is provided to improve the prognosis of the patients. However, the ever-increasing number of about 2.2 million new cases of lung cancer each year along with an increase in its causative factors like tobacco smoking and air pollutants, demand newer and more effective therapies to control the disease. The treatment is usually started with chemotherapy, which is mostly given parenterally, which gives higher systemic concentration than the lung tissue, leading to non-selective action and generally has lower patient compliance. In this article, we aim to review the use of nanocarriers like carbon nanotubes, dendrimers, quantum dots, micelles, magnetic nanoparticles, gold nanoparticles, and liposomes for targeted lung cancer treatment. Comparison of several clinical trials shows the superiority of lipid-based nanocarriers called liposomes, and their use through the pulmonary route to control the cancer growth as well as selective accumulation in the lung tissue, slow-release, and higher effectiveness, with least adverse effects. Liposomes are a tiny bubble, spherical vesicles which have at least one lipid bilayer. We have also addressed the challenges related to factors like drug resistance, particle size, etc., faced during incorporation of antineoplastic agents into the liposomes and ways to overcome them. Lastly, we have addressed the wide scope of inhalational liposomal treatment as a course of medical care in lung cancer and its future prospects.